WO2005023753A1 - Procede de preparation de chlorhydrate de memantine - Google Patents
Procede de preparation de chlorhydrate de memantine Download PDFInfo
- Publication number
- WO2005023753A1 WO2005023753A1 PCT/CN2003/001094 CN0301094W WO2005023753A1 WO 2005023753 A1 WO2005023753 A1 WO 2005023753A1 CN 0301094 W CN0301094 W CN 0301094W WO 2005023753 A1 WO2005023753 A1 WO 2005023753A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- formic acid
- urea
- memantine hydrochloride
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
- C07C209/06—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms
- C07C209/08—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention relates to a method for synthesizing memantine hydrochloride, a drug for treating moderate to severe Alzheimer's desease (AD). Background technique
- Memantine hydrochloride is an old drug that was marketed by Merz in Germany in 1982. It is still used as a treatment for Parkinson's disease, central tonic disease and dementia syndrome under the trade name Akatinol in a few countries such as Germany. Later, it was discovered that memantine hydrochloride has the action mechanism of N-methyl-D-aspartate receptor antagonists, and it has gradually attracted clinical and market attention. At present, memantine hydrochloride has been approved by the European Union as an effective drug for the treatment of moderate to severe AD, and it has become the first effective drug to be officially approved so far for the treatment of moderate to severe Alzheimer's disease. The US has also completed a phase III clinical trial and has filed a new drug application with the FDA.
- memantine hydrochloride will occupy an important position in the treatment of dementia.
- it also has deep potential for use as a therapeutic drug for moderate to severe vascular dementia, and there is currently no effective clinical option in this field, so it is an important drug with great clinical value and strong market potential.
- U.S. Patent No. 3,391,142 is brominated with 1,3-dimethyladamantane to give 1-bromo-3,5-dimethyladamantine, and then subjected to acetamidation under the action of acetonitrile and concentrated sulfuric acid, extracted with benzene and dried , Concentrated to obtain 1-acetylamino-3,5-dimethyladamantine, and then alcoholysis with sodium hydroxide and diethylene glycol, benzene extraction, and concentrated to obtain crude memantine, and then hydrochloric acid to form a salt, ethanol / ether Memantine hydrochloride was prepared by recrystallization and purification.
- This method uses acetonitrile, benzene, ether and other reagents that are harmful to the environment and the human body during the acetylamidation and recrystallization process.
- the acetyl group is difficult to hydrolyze and has many by-products. The color is very dark, and the purity of the product is difficult to meet the pharmaceutical standards, so it needs to be improved.
- U.S. Patent No. 4,122,193 uses 1-chloro-3,5-dimethyladamantine as a raw material, and reacts with urea at 220 in a sealed tube. After the reaction is completed, the reaction mixture is lumped, and the solid is pulverized and adjusted to porridge with water. After acidification treatment, adjust the pH to 3 ⁇ 5, extract with ether to remove impurities, adjust the pH of the aqueous layer to 12-13, and combine the organic layers after multiple extractions with ether. After drying, pass the hydrogen chloride gas to form a salt to obtain memantine hydrochloride. In this method, the tube is sealed and the reaction temperature is high. The reaction product is easy to agglomerate, and it is difficult to realize industrial production. Summary of the invention
- the technical problem to be solved by the present invention is to disclose a new method for preparing memantine hydrochloride to overcome the above-mentioned shortcomings of the prior art, and provide a process that is more favorable for industrial operation.
- 1-bromo-3,5-dimethyladamantane and urea / formic acid are used for the amination reaction.
- Formic acid is used as a solvent, and then hydrolyzed with an inorganic acid aqueous solution. After alkalization, the solvent is reacted with hydrochloric acid to form a salt. The target product memantine hydrochloride was then collected from the reaction product.
- the specific preparation method of the present invention includes the following steps:
- the salt can be recrystallized by using a recrystallizing solvent to obtain the hydrochloride
- the molar ratio of 1-bromo-3,5-dimethyladamantane to urea and formic acid is preferably 1: 2-5: 5-10, and the reaction temperature is preferably 60-150 ° C.
- the inorganic acid includes one of hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid and a mixture thereof.
- the inorganic base includes one of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate or potassium bicarbonate, and mixtures thereof.
- the organic solvent for extraction includes one of hydrocarbons, esters or ethers, and mixtures thereof.
- the hydrocarbons include benzene, toluene, xylene, cyclohexane, hexane or petroleum ether; the esters include ethyl acetate or butyl acetate;
- the ethers include ether or isopropyl ether
- Recrystallization solvents are preferably alcohols (such as methanol, ethanol, propanol, isopropanol, butanol, tert-butanol), ketones (such as acetone, methyl ethyl ketone), and water, and also include mixtures of the above solvents.
- alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butanol
- ketones such as acetone, methyl ethyl ketone
- water and also include mixtures of the above solvents.
- the invention adopts a new preparation method, uses cheap and readily available raw materials, the reaction is performed under homogeneous conditions, mild conditions, simple post-treatment, high reaction yield, and good product purity.
- the preparation method is easy to achieve large-scale production.
- the present invention is improved on the basis of the literature. Formic acid is added to a mixture of 1-bromo-3,5-dimethyladamantane and urea to make it react without sealing the tube. The reaction is at a lower temperature. It can be carried out, and the reactants are homogeneous and non-caking, which is convenient for post-processing, overcomes a major difficulty in industrialized production, and creates favorable conditions for large-scale production.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03785457T ATE519731T1 (de) | 2003-09-10 | 2003-12-19 | Verfahren zur herstellung von memantinhydrochlorid |
AU2003296199A AU2003296199A1 (en) | 2003-09-10 | 2003-12-19 | A method of preparing memantine hydrochloride |
EP03785457A EP1674446B1 (en) | 2003-09-10 | 2003-12-19 | A method of preparing memantine hydrochloride |
US10/575,948 US7355080B2 (en) | 2003-09-10 | 2003-12-19 | Method of preparing memantine hydrochloride |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03150892.8 | 2003-09-10 | ||
CNB031508928A CN1240668C (zh) | 2003-09-10 | 2003-09-10 | 一种新的盐酸美金刚制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005023753A1 true WO2005023753A1 (fr) | 2005-03-17 |
Family
ID=34240661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/001094 WO2005023753A1 (fr) | 2003-09-10 | 2003-12-19 | Procede de preparation de chlorhydrate de memantine |
Country Status (6)
Country | Link |
---|---|
US (1) | US7355080B2 (zh) |
EP (1) | EP1674446B1 (zh) |
CN (1) | CN1240668C (zh) |
AT (1) | ATE519731T1 (zh) |
AU (1) | AU2003296199A1 (zh) |
WO (1) | WO2005023753A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1820792A1 (en) | 2006-02-21 | 2007-08-22 | Hexal Ag | Process for the preparation of adamantanamines |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1836157T1 (sl) * | 2005-01-11 | 2009-12-31 | Teva Pharm Fine Chemicals Srl | Postopek priprave 1-amino-3,5-dimetiladamantan hidroklorida |
EP1908748A1 (en) * | 2006-10-05 | 2008-04-09 | Krka | Process for the preparation of memantine and its hydrochloric acid salt form |
US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
HRP20090186A2 (hr) | 2009-03-31 | 2010-10-31 | Institut Ruđer Bošković | Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona |
WO2012051333A1 (en) | 2010-10-12 | 2012-04-19 | The Johns Hopkins University | Antitussive compositions comprising memantine |
CN102432473A (zh) * | 2011-11-23 | 2012-05-02 | 广州博济医药生物技术股份有限公司 | 一种盐酸美金刚的合成方法 |
CN103833555B (zh) * | 2012-11-23 | 2016-12-21 | 上海京新生物医药有限公司 | 一种盐酸美金刚的制备方法 |
CN104592039B (zh) * | 2013-10-31 | 2018-09-28 | 江苏万邦生化医药股份有限公司 | 制备高纯度盐酸美金刚的方法 |
CN103664640A (zh) * | 2013-12-18 | 2014-03-26 | 成都医路康医学技术服务有限公司 | 盐酸美金刚的制备方法 |
JP6354701B2 (ja) * | 2015-08-19 | 2018-07-11 | 大日本印刷株式会社 | 高純度メマンチン塩酸塩の製造法 |
CN106966909B (zh) * | 2016-09-06 | 2019-04-12 | 南京优科制药有限公司 | 一种盐酸美金刚的纯化方法 |
CN114767700A (zh) * | 2022-06-01 | 2022-07-22 | 江苏长泰药业有限公司 | 盐酸美金刚联合用药在制备激活血管性痴呆海马区bdnf蛋白表达的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4122193A (en) * | 1972-04-20 | 1978-10-24 | Merz & Co. | Drugs or medicines for influencing the central nervous system |
US5061703A (en) * | 1989-04-14 | 1991-10-29 | Merz + Co. Gmbh & Co. | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
CN1335299A (zh) * | 2001-08-29 | 2002-02-13 | 中国科学院广州化学研究所 | 美金刚胺盐酸盐的合成方法 |
CN1400205A (zh) * | 2002-08-30 | 2003-03-05 | 中国科学院广州化学研究所 | 美金刚胺盐酸盐的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ288445B6 (en) * | 1996-06-20 | 2001-06-13 | Lachema Np | Process for preparing hydrochloride of 5-amino-1,3-dimethyltricyclo(3,3,1,1 3,7 )decane |
-
2003
- 2003-09-10 CN CNB031508928A patent/CN1240668C/zh not_active Expired - Lifetime
- 2003-12-19 EP EP03785457A patent/EP1674446B1/en not_active Expired - Lifetime
- 2003-12-19 WO PCT/CN2003/001094 patent/WO2005023753A1/zh active Application Filing
- 2003-12-19 AU AU2003296199A patent/AU2003296199A1/en not_active Abandoned
- 2003-12-19 US US10/575,948 patent/US7355080B2/en not_active Expired - Lifetime
- 2003-12-19 AT AT03785457T patent/ATE519731T1/de not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4122193A (en) * | 1972-04-20 | 1978-10-24 | Merz & Co. | Drugs or medicines for influencing the central nervous system |
US5061703A (en) * | 1989-04-14 | 1991-10-29 | Merz + Co. Gmbh & Co. | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
CN1335299A (zh) * | 2001-08-29 | 2002-02-13 | 中国科学院广州化学研究所 | 美金刚胺盐酸盐的合成方法 |
CN1400205A (zh) * | 2002-08-30 | 2003-03-05 | 中国科学院广州化学研究所 | 美金刚胺盐酸盐的制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1820792A1 (en) | 2006-02-21 | 2007-08-22 | Hexal Ag | Process for the preparation of adamantanamines |
Also Published As
Publication number | Publication date |
---|---|
US7355080B2 (en) | 2008-04-08 |
AU2003296199A1 (en) | 2005-03-29 |
CN1594277A (zh) | 2005-03-16 |
EP1674446A1 (en) | 2006-06-28 |
CN1240668C (zh) | 2006-02-08 |
EP1674446B1 (en) | 2011-08-10 |
US20070078283A1 (en) | 2007-04-05 |
ATE519731T1 (de) | 2011-08-15 |
EP1674446A4 (en) | 2009-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005023753A1 (fr) | Procede de preparation de chlorhydrate de memantine | |
CN110950765A (zh) | 一种硫酸特布他林的制备方法 | |
EP2590943A1 (en) | Process and intermediates for preparation of an active ingredient | |
CN114634441B (zh) | 一种合成6,6-二甲基-3-氮杂双环[3,1,0]己烷的方法 | |
HU228204B1 (en) | New process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and use thereof for the synthesis of tianeptine | |
JP2004527577A (ja) | 4−フェニル酪酸の合成 | |
CN102351778A (zh) | 一种盐酸阿比朵尔的制备方法 | |
EP1347951B1 (en) | A process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid | |
CN109180532B (zh) | D-三七素的高效制备方法 | |
EP2358654A1 (en) | An improved process for the preparation of 1-bromo-3,5-dimethyl adamantane | |
ES2409692T3 (es) | Método para la producción de memantina | |
CN110872251A (zh) | N-乙基吡啶甲胺三氟乙酸盐及其晶体、制备工艺和应用 | |
HU229188B1 (hu) | Új eljárás N-[(S)-1-karboxibutil]-(S)-alanin-észterek elõállítására, és a perindopril szintézisnél történõ alkalmazása | |
AU2015242231B2 (en) | A process for preparation of Levothyroxine and salts thereof | |
CN111978328B (zh) | 一种替格瑞洛的合成方法 | |
WO2009153806A2 (en) | Process for preparing memantine hydrochloride substantially free of !mpurities | |
CN101844989B (zh) | 一种氯苯达诺及其盐酸盐的制备方法 | |
CN112939814A (zh) | 一种氘代达卡他韦中间体的制备方法 | |
CN101412678B (zh) | 一种合成盐酸美金刚的方法 | |
EP2555616A1 (en) | Process for the preparation of memantine hydrochloride | |
CN112094241B (zh) | 一种1,4-二氮杂螺[5,5]十一烷-3-酮的制备方法 | |
CN106542961A (zh) | 一种消旋卡多曲中间体的合成方法 | |
CN116924929A (zh) | 一种碘比醇异构体的合成方法 | |
CN118146111A (zh) | 一种奥司他韦酸甲酯的制备方法 | |
CN103319482B (zh) | 一种合成1-羟甲基-3-氢-2-氮杂金刚烷的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003785457 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003785457 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007078283 Country of ref document: US Ref document number: 10575948 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10575948 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |